Study drug for solid tumors with MTAP gene deletion
Part of Brain & nervous system, Cancer, Digestive system, Hormones & metabolism, Lungs & breathing clinical trials.
This Phase 1 trial studies MRTX1719, a new medicine, in solid tumors that have a missing MTAP gene (MTAP deletion). It aims to find the safest dose and check how the drug affects the tumor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be an adult (age 18 or older) with a solid tumor confirmed by tissue testing.
- Your tumor tissue must show MTAP is missing in a “homozygous deletion” pattern on the test results.
- Your cancer must be unresectable (can’t be removed by surgery) or metastatic (spread to other parts of the body).
- You must be well enough to take part (ECOG 0 or 1) and have enough organ function based on blood/health tests.
- You will need a tumor biopsy at the start (and again during the study) if it’s safe and possible.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called CTS3497 in people whose tumors lack a protein called MTAP. The drug aims to stop cancer cells from growing by targeting a weakness caused by this missing protein.
This trial tests an investigational drug called HSK41959 combined with standard cancer therapy for people whose tumors have a specific genetic change (MTAP deletion). The goal is to see if the combination is safe and works better against advanced solid tumors, including non-small cell lung cancer and pancreatic cancer.
This trial tests a new drug (GS-5319) for adults with advanced solid tumors that have a specific genetic feature called MTAP deficiency. The drug may be given alone or with another treatment, and the goal is to see if it can shrink tumors or slow their growth.
This trial tests a new drug called BMS-986504 in people whose mesothelioma has come back after treatment and whose tumors lack a protein called MTAP. The drug may help by blocking a specific pathway that these cancer cells need to grow.
This trial tests a combination of two drugs (BMS-986504 and olaparib) for people with advanced solid tumors that have a specific genetic change called MTAP loss. It aims to see if this combination can help when standard treatments have stopped working or aren't available.
This trial tests a new drug called PEP08 for people with advanced solid tumors that have a specific genetic change (MTAP deletion). It might be an option if standard treatments no longer work or cause too many side effects.
Hear when a new Mesothelioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.